Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
RegeneRx Biopharmaceuticals (RGRX)
OTHER OTC:RGRX
RegeneRx Biopharmaceuticals (RGRX) Stock Price & Analysis
79 Followers
RGRX Stock Chart & Stats
Day’s Range$0.05 - $0.05
52-Week Range― - ―
Previous Close$0.0014
Volume83.00
Average Volume (3M)N/A
Market Cap
$78.14K
Enterprise ValueN/A
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)N/A
BetaN/A
Next Earnings
May 15, 2018EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. VolumeN/A
30 Day Avg. VolumeN/A
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
RGRX FAQ
What was RegeneRx Biopharmaceuticals’s price range in the past 12 months?
Currently, no data Available
What is RegeneRx Biopharmaceuticals’s market cap?
Currently, no data Available
When is RegeneRx Biopharmaceuticals’s upcoming earnings report date?
RegeneRx Biopharmaceuticals’s upcoming earnings report date is May 15, 2018 which is 2177 days ago.
How were RegeneRx Biopharmaceuticals’s earnings last quarter?
Currently, no data Available
Is RegeneRx Biopharmaceuticals overvalued?
According to Wall Street analysts RegeneRx Biopharmaceuticals’s price is currently Overvalued.
Does RegeneRx Biopharmaceuticals pay dividends?
RegeneRx Biopharmaceuticals does not currently pay dividends.
What is RegeneRx Biopharmaceuticals’s EPS estimate?
RegeneRx Biopharmaceuticals’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does RegeneRx Biopharmaceuticals have?
Currently, no data Available
What happened to RegeneRx Biopharmaceuticals’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of RegeneRx Biopharmaceuticals?
Currently, no hedge funds are holding shares in RGRX
---
RegeneRx Biopharmaceuticals Stock Smart Score
Not Ranked
1
2
3
4
5
6
7
8
9
10
Company Description
RegeneRx Biopharmaceuticals
RegeneRx Biopharmaceuticals, Inc. focuses on the development of a novel therapeutic peptide, Thymosin beta 4, or Tß4, for tissue and organ protection, repair, and regeneration. Its products include RGN-259, RGN-352, and RGN-137. The company was founded by Allan L. Goldstein on May 13, 1982 and is headquartered in Rockville, MD.
---
Technical Analysis
---